Luis R. T.
- Country
- Spain
- Department
- #5410 :neurologia
Research Overview
- A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
- Long-term Safety, Tolerability, and Efficacy Evaluation of Ofatumumab in Patients with Relapsing Multiple Sclerosis: An Open-label Extension Study
Data & Insights
Has run more than one trial at 22 of 145 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the treatment and research of relapsing multiple sclerosis (RMS), focusing on innovative therapeutic approaches for managing this chronic neurological condition.
- Disease-modifying therapies
- Autoimmune neurological conditions
- Long-term disease management
Their work encompasses evaluation of novel therapeutic agents and comparative effectiveness studies in RMS treatment.
Therapeutic Innovation
The investigator's research involves studying advanced treatments including ofatumumab and remibrutinib, exploring their potential in managing neurological autoimmune conditions.
- Novel therapeutic agents
- Treatment effectiveness assessment
- Safety monitoring protocols
Their expertise extends to evaluating long-term safety profiles and therapeutic efficacy of emerging treatments.
Clinical Assessment
The investigator focuses on comparative therapeutic studies and evaluation of treatment outcomes in multiple sclerosis patients.
- Relapse frequency assessment
- Long-term safety monitoring
- Treatment tolerability studies
Their research encompasses comprehensive evaluation of therapeutic responses and patient outcomes in neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.